RECRUITING
I'm interested ...!!
WithDRawal Impact Of Postoperative Beta-Blocker
The investigators will evaluate the impact of withdrawing beta-blocker medication after coronary artery bypass surgery with this randomized controlled trial.
Conditions:
🦠 Coronary Artery Bypass
🗓️ Study Start (Actual) 4 November 2022
🗓️ Primary Completion (Estimated) December 2024
✅ Study Completion (Estimated) December 2025
👥 Enrollment (Estimated) 406
🔬 Study Type INTERVENTIONAL
📊 Phase NA
Locations:
📍 New Haven, Connecticut, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • * Participants who underwent coronary artery bypass graft(CABG) surgery at Yale New Haven Hospital who presented to 1-month postoperative visit
    • * ejection fraction \>50%, and in sinus rhythm at the time of hospital discharge or enrollment.

    Exclusion Criteria:

    • * those who underwent combined valve + CABG surgery or aorta + CABG surgery.
Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 7 June 2022
  • First Submitted that Met QC Criteria 7 June 2022
  • First Posted 10 June 2022

Study Record Updates

  • Last Update Submitted that Met QC Criteria 9 May 2024
  • Last Update Posted 13 May 2024
  • Last Verified May 2024
I'm interested ...!!